REPRIEVE Trial

09/28/2023

¿Se pregunta cómo las personas con VIH pueden proteger la salud de su corazón? ¡Únase a nosotros para un foro comunitario virtual mañana a las 11:00 a. m., hora del este! https://www.reprievetrial.org/for-participants/community-forum/

09/20/2023

We are excited to share that REPRIEVE will be hosting two Community Forums to review the primary results of REPRIEVE during the month of September! These will be held on Thursday, September 21st at 1:00 PM ET (English) and Friday, September 29th at 11:00 AM ET (Spanish).

Join us tomorrow at 1:00 PM ET to learn about REPRIEVE and what the trial's results mean for people with HIV! For more information, visit our website: https://www.reprievetrial.org/for-participants/community-forum/

09/12/2023

Thanks to lifesaving drugs, people with HIV are proudly achieving aging milestones. Now, researchers have been searching for ways to keep this community healthier in their later years. Read more in The New York Times: https://www.nytimes.com/2023/09/10/health/hiv-aging-statins.html
AIDS Clinical Trials Group National Heart, Lung, and Blood Institute (NHLBI) National Institute of Allergy and Infectious Diseases (NIAID)

07/25/2023

The REPRIEVE Trial demonstrates that pitavastatin lowers the incidence rate of heart disease events by 35% in people with HIV. Read the results in :

Original Article from The New England Journal of Medicine — Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

04/11/2023

: Taking a daily statin medication has been found to reduce the excess risk of cardiovascular disease (CVD) among people living with HIV in , the first large-scale clinical trial testing a CVD preventive strategy in this population. Read the full NIH press release here:

Premature heart disease and other chronic conditions have emerged as leading causes of morbidity and mortality.